GHIC supports innovation to improve global public health.
GHIC’s portfolio of technology companies and investment funds are developing and deploying diagnostics, vaccines, pharmaceuticals, and other medical products and have been catalytic in the launch of registered products that have reached more than 500 million people worldwide.
Our namesake $108 million social impact fund (GHIF) invested in twelve companies developing clinical diagnostics, devices, vaccines, and therapeutics targeting diseases such as HIV/AIDS, malaria, tuberculosis, and cholera. The fund's portfolio companies have successfully commercialized more than a dozen products that have been delivered to over 500 million people.
Read more about GHIF
In partnership with the Biomedical Advanced Research and Development Authority (BARDA), GHIC uses venture capital investments to accelerate the development and commercialization of technologies that respond to or prevent public health emergencies, such as pandemics and other global health security threats.
Read more about Global Health Security and our BARDA partnership
CHIP is a 20-year partnership between GHIC and the Government of Germany, through its Public Development Bank KfW, to accelerate the development of public health technologies and products to improve global health. CHIP catalyzes health innovation to address the needs of underserved populations in low- and middle-income countries through investments in funds and companies as well as grant making opportunities.
Read more about CHIP
Intervention: Diagnostic
Intervention: Device
Intervention: Biosynthesis Manufacturing Platform
Intervention: Predictive vaccine design platform
Intervention: Diagnostic
Intervention: Diagnostic
Intervention: Device
Intervention: Bioinformatics platform
Intervention: Vaccine platform
Intervention: Cellular host response diagnostic
Intervention: Therapeutic + Companion Diagnostic
Intervention: Diagnostic
Intervention: Vaccine
Intervention: Diagnostic
Intervention: Surgical device
Intervention: NGS sample prep
Intervention: Vaccine and drug delivery
Intervention: Treatment
Intervention: Biomanufacturing
Intervention: Treatment
Intervention: Data intelligence platform
Intervention: Vaccines and therapeutics
Intervention: Vaccine platform
Investment Type: Fund Investment
Intervention: Biomanufacturing technology platform and CDMO
Intervention: Vaccine delivery
Intervention: Vaccine development
Intervention: Antiviral development
Adjuvant Capital was formed by several GHIF alumni to accelerate the development of new technologies to address public health challenges. GHIC supported Adjuvant Capital Fund’s launch with an anchor investment, with generous financial support from the Government of Germany.
The Women’s and Children’s Health Technology Fund, launched by Cross Border Impact Ventures, invests in health technology companies that address the health needs of women, children, and adolescents or make health systems more resilient. GHIC has supported the Fund’s launch with an anchor investment, with the financial support from the Government of Germany, through its KfW development bank.
